✦ LIBER ✦

Denosumab and Alendronate Have Different Effects at the Ultradistal Radius in Postmenopausal Women With Low Bone Mass

✍ Scribed by Cesar Libanati; Ego Seeman; Thierry Thomas; Steven Boyd; Stephanie Boutroy; Elizabeth Shane; David Hanley; Cesar Bogado; Angela Cheung; Sharmila Majumdar; Deborah Sellmayer; Ann Kearns; Pierre Delmas; Michelle Fan; Jose Zanchetta

Book ID: 116322750
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 70 KB
Volume: 46
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2010.01.057

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of denosumab and alendronate at

Effects of denosumab and alendronate at the ultradistal radius in postmenopausal women with low bone mass

✍ E. Seeman; T. Thomas; S.K. Boyd; S. Boutroy; E. Shane; D.A. Hanley; C. Bogado; A 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Comparative effects of raloxifene and al

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass

✍ Robert R. Recker; David Kendler; Christopher P. Recknor; Theodore W. Rooney; E. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 265 KB

The double-blind, randomized raloxifene alendronate comparison trial was the first study designed to compare two osteoporosis therapies head-to-head for fracture risk reduction. The original protocol planned to treat 3000 postmenopausal women with alendronate 10 mg/day (ALN) or raloxifene 60 mg/day

Denosumab improves density and strength

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

✍ H.K. Genant; K. Engelke; D.A. Hanley; J.P. Brown; M. Omizo; H.G. Bone; A.J. Kivi 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 547 KB

Multinational, Placebo-Controlled, Rando

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

✍ H. A. P. Pols; D. Felsenberg; D. A. Hanley; J. Štepán; M. Muñoz-Torres; T. J. Wi 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 86 KB

Rapid Onset and Sustained Efficacy (ROSE

Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass

✍ P. Hadji; D. Gamerdinger; W. Spieler; P. H. Kann; H. Loeffler; K. Articus; R. Mö 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 228 KB

Effects of multiple doses of the scleros

Effects of multiple doses of the sclerostin antibody AMG 785 in healthy men and postmenopausal women with low bone mass

✍ D. Padhi⁎; M. Allison; A.J. Kivitz; M.J. Gutierrez; B. Stouch; C. Wang; G. Jang 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 178 KB